Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
vedolizumab
C13007
NCT00783692
2008-002783-33
Ulcerative Colitis; Crohn's Disease
Phase 3
 
October 2014

Powered by ideaPoint, Inc.